Cardiac Troponin-I (cTnI) is specific to cardiomyocytes and is released into the bloodstream following heart damage. Extensive studies have shown that cTnI is slowly released from damaged cardiomyocytes. This has allowed cTnI to become widely accepted in preclinical and clinical drug development settings as an indicator of myocardial damage and hence, heart damage.The high sensitivity of the research grade Erenna cTnI assay uniquely provides utility across multiple species and matrices.
The SMC® Human cTnI Immunoassay Kit contains all reagents required to perform the assay. This assay takes advantage of a standard immunoassay workflow configured in a standard plate format. Assay protocols are similar to existing sandwich ELISA methods with two key differences: 1) Elution buffer disrupts the sandwich, separating the labeled detection antibody for quantification. 2) The SMC® immunoassay system detects analytes using Single Molecule Counting (SMC®) technology.
Research Sub Category
The sensitivity of the Single Molecule Counting (SMC®) technology gives the SMC® Cardiac Troponin (cTnI) Immunoassay Kit unparalleled performance in the quantification of cTnI in human EDTA plasma and serum.
Used to detect/quantify:Cardiac Troponin I
cTnI Coated Beads
cTnI Detection Antibody
10X Wash Buffer
Elution Buffer B
SMC® Human cTnI Immunoassay Kit Instructions
Low-end CV% Range: 0-20%|Low-end CV% Average: 12%
SMC is a registered trademark of Singulex
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial